Intellia Therapeutics (NTLA) announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of Ziclumeran, nex-z, for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy, respectively. This action follows a report on October 24, 2025 of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial on September 30, 2025, meeting the trial’s protocol-defined pausing criteria. The patient was hospitalized, is being closely monitored and is receiving medical intervention. Intellia is consulting with experts, considering potential risk mitigation strategies and engaging with regulatory authorities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics rises 23.8%
- Intellia upgraded to Outperform from Market Perform at Citizens JMP
- CoreWeave, NuScale, Southern Co, Intellia, and Prospect Capital: Insider Moves Unveiled!
- Private Markets: Cerebras raises $1B in pre-IPO funding round
- Unusually active option classes on open October 2nd